IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award
05 6월 2023 - 9:30PM
Business Wire
IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the "Company"),
today announced that its Advisor, Professor T. Govindaraju the
inventor of the investigational Alzheimer’s drug candidate, TGR-63,
received the Government of India-instituted National Technology
Award (Translational Research) for “Outstanding Contribution in
Commercializing Innovative Indigenous Technologies” from the
Minister of State for Science and Technology and Earth
Sciences.
IGC Pharma, Inc., acquired exclusive rights to TGR-63 from
researchers at India-based Jawaharlal Nehru Centre for Advanced
Scientific Research (JNCASR) that created the TGR-63 molecule.
Pre-clinical testing demonstrates that TGR-63 holds the potential
to ameliorate amyloid plaque a key hallmark of Alzheimer’s disease.
Behavioral tests with Alzheimer’s (APP/PS1) mice show that TGR-63
can rescue neuronal cells from amyloid toxicity and minimize
learning deficiency, memory impairment & cognitive decline. IGC
Pharma is progressing TGR-63 through trials leading to the Phase 1
trial.
The Department of Science and Technology (DST)-Technology
Development Board (TDB), Government of India recognized Professor
Govindaraju with the prestigious award on May 14, 2023. National
Technology Awards are prestigious accolades acknowledging
excellence and success in the commercialization of technology
indigenous to India. Professor Govindaraju is celebrated for his
innovative approach to developing therapeutics.
Professor Govindaraju received his PhD from CSIR-National
Chemical Laboratory in Pune and did postdoctoral studies at the
University of Wisconsin-Madison (USA) and the Max Planck Institute
for Molecular Physiology in Dortmund (Germany).
About IGC Pharma, Inc.
IGC Pharma, Inc., (dba IGC) develops advanced cannabinoid-based
formulations for treating diseases and conditions, including, but
not limited to, Alzheimer’s disease, period cramps
(“dysmenorrhea”), premenstrual syndrome (“PMS”), and chronic pain.
IGC has two investigational drug assets targeting Alzheimer’s
disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s
cell lines the potential to be effective in suppressing or
ameliorating key hallmarks of Alzheimer’s disease, such as plaques
or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”)
based formulation that is currently in a 146-person Phase 2
clinical trial for agitation in dementia due to Alzheimer’s
(clinicaltrials.gov, NCT05543681). IGC Pharma, Inc., also markets a
wellness brand, Holief™, that targets women experiencing
premenstrual syndrome and menstrual cramps. For more information
visit https://igcpharma.com/
Forward-looking
Statements
This press release contains forward-looking statements. These
forward-looking statements are based largely on IGC’s expectations
and are subject to several risks and uncertainties, certain of
which are beyond IGC’s control. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, the Company’s failure or inability to
commercialize one or more of the Company’s products or
technologies, including the products or formulations described in
this release, or failure to obtain regulatory approval for the
products or formulations, where required; general economic
conditions that are less favorable than expected, including as a
result of the ongoing COVID-19 pandemic; the FDA’s general position
regarding cannabis- and hemp-based products; and other factors,
many of which are discussed in IGC’s U.S. Securities and Exchange
Commission (“SEC”) filings. IGC incorporates by reference the human
trial disclosures and Risk Factors identified in its Annual Report
on Form 10-K filed with the SEC on June 23, 2022, as if fully
incorporated and restated herein. In light of these risks and
uncertainties, there can be no assurance that the forward-looking
information contained in this release will occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005341/en/
Investors IMS Investor Relations Walter Frank
igc@imsinvestorrelations.com (203) 972-9200
IGC Pharma (AMEX:IGC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IGC Pharma (AMEX:IGC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024